Hyperlipidemia-controlling

Derivatives of clofibric acid were used in earlier times as hyperlipidemia-controlling drugs. Currently more interest is shown in the synthesis of 2-methyl-2-aryloxypropanoic acids because these classes of compounds are being considered as possible remedies for type II diabetes. The earlier GSK process involves reacting 2-bromo-2-methylpropanoic acid with a phenolic compound at 50°C, where both compounds are suspended in 2-butanone solvent. The acid is expensive, and large volumes of the organic solvent are also required. 

Hypertension for 12 years, currently controlled Hyperlipidemia for 10 years, currently controlled Osteoarthritis for 5 years... 

The cornerstone of treatment in primary hyperlipidemia is diet restriction and weight reduction. Limit or eliminate alcohol intake. Use drug therapy in conjunction with diet, and after maximal efforts to control serum lipids by diet alone prove unsatisfactory, when tolerance to or compliance with diet is poor or when hyperlipidemia is severe and risk of complications is high. Treat contributory diseases such as hypothyroidism or diabetes mellitus. 

Hyperlipidemia, secondary causes Prior to initiating therapy, exclude secondary causes of hyperlipidemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) and measure total-C, HDL-C, and triglycerides. 

To treat hyperuricemia associated medical problems the following steps are recommended life-style corrections by restriction of purine-rich nutrition, prevention and reduction of obesity, bloodpressure control, limitation of alcohol consumption and control of hyperlipidemia. 

Prazosin may be particularly useful when patients cannot tolerate other types of antihypertensive agents or when blood pressure is not well controlled by other drugs. Since prazosin does not significantly influence blood uric acid or glucose levels, it can be used in hypertensive patients whose condition is complicated by gout or diabetes meUitus. Prazosin treatment is associated with favorable effects on plasma lipids. Thus, it may be of particular importance in managing patients with hyperlipidemia. 

The major steps in the management of patients with chronic heart failure are outlined in Table 13-3. The ACC/AHA 2005 guidelines suggest that treatment of patients at high risk (stages A and B) should be focused on control of hypertension, hyperlipidemia, and diabetes, if present. Once symptoms and signs of failure are present, stage C has been entered, and active treatment of failure must be initiated. 

A, 1 Control hypertension, hyperlipidemia, glucose metabolism (diabetes), obesity... 

The two major clinical sequelae of hyperlipidemias are acute pancreatitis and atherosclerosis. The former occurs in patients with marked hyperlipemia. Control of triglycerides can prevent recurrent attacks of this life-threatening disease. 

The incidence of acute pancreatitis as a suspected complication of finasteride treatment has been examined in a case-control study in a Danish regional population of 490 000 over 7 years. Of 302 men aged 60 and older with incident acute pancreatitis, three had been exposed to finasteride of 2994 controls 37 had been exposed to finasteride. After adjustment for alcohol-related diseases, gallstone disease, hyperlipidemia, hypercalcemia, and hyperparathyroidism, the authors found no evidence of an increased risk of acute pancreatitis in users of finasteride (48). 

A 10-year-old child had status epilepticus controlled with a combination of valproate, oxcarbazepine, and 48 hours of propofol infusion in a dose of 5.5 mg/kg/ hour. After weaning from propofol, a classic ketogenic diet was instituted in an attempt to provide long-term control of the seizures. A day later status epilepticus recurred and propofol was restarted at a rate of 6-9 mg/ kg/hour to suppress seizure activity (the diet, valproate, and oxcarbazepine were also continued). Shortly thereafter, he developed the classical constellation of malignant ventricular arrhythmias, hyperlipidemia, rhabdomyolysis, lactic acidosis, and biventricular cardiac failure. He did not survive. 

In a 1-year follow-up of 40 renal transplant patients treated with various dosages of sirolimus (0.5-7 mg/m2/ day) in addition to a ciclosporin-based regimen, there were significant increases in serum cholesterol and triglycerides, and significant falls in white blood cell and platelet counts, compared with historical controls (1066). These effects correlated with sirolimus trough concentrations but not dosages. One patient had to discontinue sirolimus because of hyperlipidemia refractory to treatment. 

Although it is not exactly clear how much these agents can reduce the risk of a major cardiac event (e.g., infarction, stroke), these drugs will probably remain the first choice for people with certain hyper-lipidemias (e.g., increased triglycerides). These drugs are likewise advocated for mixed hyperlipidemias that are common in metabolic disorders such as type 2 diabetes mellitus (see Chapter 32).32,141 Certain fibrates can be used with other drugs, such as statins, to provide more comprehensive pharmacologic control of certain lipid disorders.30,147... 

Although hormonal contraceptives provide an easy and effective means of birth control, their use has been limited somewhat by potentially serious side effects. In particular, contraceptive medications have been associated with cardiovascular problems such as thrombophlebitis, stroke, and myocardial infarction.153 The incidence of these adverse effects, however, seems to depend to a large extent on whether the user has other risk factors associated with cardiovascular disease (smoking cigarettes, hyperlipidemia, hypertension, and so forth).84,120,162 Likewise, cardiovascular risks may be diminished with the newer forms of hormonal contraceptives, which contain relatively less estrogen than their predecessors. 

Diet is a strong factor in the control of atherosclerosis relating to general vascular disease, coronary heart disease, and stroke. The interrelated disorders in atherosclerosis of hyperinsulinemia, hyperlipidemia, and hypertension are strongly subject to dietary influence. The type of dietary protein, animal vs. plant, appears to be as important as the type of lipid, animal vs. plant, in atherosclerosis. Dietary protein type, with its differing amino acid ratios, appears to be a major secretagogue of insulin. 

In vitro, allicin and related compounds inhibit HMG-CoA reductase, which is involved in cholesterol biosynthesis (see Chapter 35 Agents Used in Hyperlipidemia). Several clinical trials have investigated the lipid-lowering potential of garlic. Some have shown significant reductions in cholesterol and others no effect. The most recent meta-analysis suggested a minor (5%) reduction of total cholesterol that was insignificant when dietary controls were in place. 

The referral form also includes check boxes for the physician to mark the appropriate ICD-9-CM codes. For diabetes education, he includes the common ICD-9 codes 250.00 (i.e., uncomplicated type 2 diabetes, controlled), 250.02 (i.e., uncomplicated type 2 diabetes, uncontrolled), and an Other field with room for the physician to add a more specific code (Buck and Lockyear, 2007). For the hyperlipidemia component, he has also included the common codes used to describe these conditions. Within the referral form is the statement of medical necessity and contact information for the physician and patients to reach the pharmacy to make appointments. Although Dr. Brouchard likes the form that he has created, he plans on revising the form based on his experience and input from the physicians office after a few months of use. He wants to make sure that the referral form is as easy to use as possible and that it contains most of the information he needs to submit claims successfully. 

Nephrotic hyperlipidemia is accompanied with increased risk of cardiovascular complications and should be treated in all patients with persistent nephrotic syndrome. The putative positive effect of hypolipidemic drugs (namely statins) on the cardiovascular risk and potentially also on the rate of progression of chronic renal failure remains to be demonstrated in prospective controlled studies. 

In lipid metabolism, there is elegant balance in the levels of end-product lipids, and the enzymes and genes involved in their biosynthesis, as well as close cooperation with other metabolisms to maintain homeostasis. When the balance is lost, obesity or hyperlipidemia will develop, leading to a variety of serious diseases including atherosclerosis, hypertension, diabetes, functional depression of certain organs, and so on. Therefore, the control of lipid metabolism by drugs could lead to the prevention or treatment of these diseases. 

Two studies evaluated the effects of lipid-lowering therapy on clinical endpoints in the leg. The Program on the Surgical Control of the Hyperlipidemias was a randomized trial of partial ileal-bypass surgery for the treatment of hyperlipidemia in 838 patients (9). After five years, the relative risk (RR) of an abnormal ankle-brachial index value (ABI) was 0.6 (95% Cl, 0.4 to 0.9, absolute risk reduction, 15% points, p < 0.01), and the RR of claudication or limb-threatening ischemia was 0.7 (95% Cl, 0.2 to 0.9, absolute risk reduction, 7% points, p < 0.01), as compared with the control group. 

Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery 1996 120 672-679. 

The promising second oral therapy is Temsirolimus (Wyeth Pharm). Temsirolimus is believed to block the proliferation of immune T cells activated by interleukin, IL-2. The phase It clinical trial of Temsirolimus was also an international double blind placebo controlled trial. The trial involved 296 patients with either RR MS or SP MS with relapses. Participants received one of three doses of oral temsirolimus or placebo daily for 9 months. The primary outcome measure was the number of enhancing lesions after 9 months in study. By 32 w eeks into the study, those in the highest treatment dose had 47.8% fewer new enhancing lesions compared to those on placebo. The high dose group also had 51 % fev er relapses than the placebo group. Side effects included mouth ulceration or inflammation, menstrual dysfunction, hyperlipidemia and rashes. 

Hyperlipidemia and the recruitment of inflammatory cells into the atherosclerotic arterial wall are suggested to cause excessive production of oxygen flee radicals [19]. Ohara et al. found that aortas from rabbits that had been fed a high cholesterol diet for several weeks produced several fold more oxygen free radicals than did control aortas [19,24]. Furthermore, removal of the endothelium resulted in reduction of free radical production, suggesting that the endothelium is a major source of the reactive oxygen species in this model. It was hypothesized that the abnormal redox state in the arterial wall may be a fundamental metabolic feature of atherosclerosis [19]. 

---